MODULATORS OF AMYLOID AGGREGATION
    9.
    发明申请
    MODULATORS OF AMYLOID AGGREGATION 审中-公开
    淀粉样聚集的调节剂

    公开(公告)号:US20110009343A1

    公开(公告)日:2011-01-13

    申请号:US12643258

    申请日:2009-12-21

    CPC分类号: C07K14/4711 A61K38/00

    摘要: Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural β amyloid peptides (β-AP). In a preferred embodiment, the β amyloid modulator compounds of the invention are comprised of an Aβ aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural β amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural β-AP aggregation when the natural β-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.

    摘要翻译: 公开了调节淀粉样蛋白形成蛋白或肽聚集的化合物。 本发明的调节剂可以促进淀粉样蛋白聚集,更优选可以抑制天然淀粉样蛋白聚集。 在优选的实施方案中,所述化合物调节天然物质的聚集。 淀粉样蛋白肽(&bgr; -AP)。 在优选实施例中, 本发明的淀粉样蛋白调节剂化合物由A&Bgr; 聚集核心结构域和与其偶联的修饰基团,使得所述化合物改变聚集或抑制天然蛋白的神经毒性; 当与肽接触时,淀粉样蛋白肽。 此外,当天然和重组相对于调节剂摩尔量过多时,调节剂能够改变天然和重组蛋白的聚集。 还公开了包含本发明化合物的药物组合物,以及使用本发明化合物的淀粉样变性疾病的诊断和治疗方法。

    Modulators of amyloid aggregation
    10.
    发明授权
    Modulators of amyloid aggregation 失效
    淀粉样蛋白聚集的调节剂

    公开(公告)号:US07658917B2

    公开(公告)日:2010-02-09

    申请号:US10463729

    申请日:2003-06-17

    CPC分类号: C07K14/4711 A61K38/00

    摘要: Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural β amyloid peptides (β-AP). In a preferred embodiment, the β amyloid modulator compounds of the invention are comprised of an Aβ aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural β amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural β-AP aggregation when the natural β-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.

    摘要翻译: 公开了调节淀粉样蛋白形成蛋白或肽聚集的化合物。 本发明的调节剂可以促进淀粉样蛋白聚集,更优选可以抑制天然淀粉样蛋白聚集。 在优选的实施方案中,化合物调节天然β淀粉样肽(β-AP)的聚集。 在优选的实施方案中,本发明的β淀粉样蛋白调节剂化合物由Abeta聚集核心结构域和与其偶联的修饰基团组成,使得当与肽接触时该化合物改变聚集或抑制天然β淀粉样肽的神经毒性。 此外,当天然β-AP相对于调节剂为摩尔过量时,调节剂能够改变天然β-AP聚集。 还公开了包含本发明化合物的药物组合物,以及使用本发明化合物的淀粉样变性疾病的诊断和治疗方法。